Car T-Cell Therapy

The advent of novel therapies has propelled, and continues to propel, tremendous progress and innovation in diffuse large B-cell lymphoma.

Younger patients who received higher doses of tisagenlecleucel for advanced B-cell acute lymphoblastic leukemia achieved better outcomes, according to results of a retrospective study.

The FDA lifted its clinical hold on a trial designed to evaluate CYAD-101, an investigational chimeric antigen receptor T-cell therapy.

Perhaps no one has been better prepared to become a leader in the field of cancer cellular immunotherapy than Marcela V. Maus, MD, PhD.

The FDA granted fast track and rare pediatric disease designations to WU-CART-007 for treatment of relapsed or refractory T-cell acute lymphoblastic leukemia, according to a press release from the agent’s manufacturer.

Researchers have developed a genetically modified form of the immune-stimulating protein interleukin-7 that significantly enhanced chimeric antigen receptor T-cell therapy activity in preclinical testing.

Koen van Besien, MD, PhD, has been appointed chief of the division of hematology at University Hospitals Seidman Cancer Center.

Nearly 40% of patients who received chimeric antigen receptor T-cell therapy required hospitalization for disease- or treatment-related reasons in the year after infusion, results of a research letter in JAMA Oncology showed.

The use of broad-spectrum antibiotics in the month leading up to chimeric antigen receptor T-cell therapy led to poorer outcomes and increased treatment-related toxicities, study results showed.

An investigational chimeric antigen receptor T-cell therapy provided via multiple infusions induced a 100% overall response rate among adults with relapsed or refractory multiple myeloma, results from a pilot study showed.